Age-related Macular Degeneration Serum
Powered by BiozAbout:Age-related Macular Degeneration Serum - human serum from clinically confirmed AMD donors, processed within 24 hours. AMD is a degenerative, complement-driven retinal disease. Ideal for complement pathway biomarker work, cytokine and VEGF profiling, oxidative stress markers, and proteomics. Stratification by dry versus neovascular subtype, stage, and anti-VEGF treatment history; matched healthy controls available.
About Age-related Macular Degeneration Serum
Age-related Macular Degeneration Serum for Complement and Retinal Degeneration Research
Our Age-related Macular Degeneration Serum is sourced from IRB-consented donors clinically diagnosed with age-related macular degeneration (AMD). Each sample is processed and frozen within 24 hours of collection to ensure consistency and high quality. AMD is a degenerative disease of the macula in which complement dysregulation, oxidative stress, and lipid deposition combine to damage the retinal pigment epithelium and photoreceptors. Serum is acellular and is the appropriate matrix for measuring complement components, activation fragments, and circulating protein and lipid biomarkers.
AMD Biology and Why Serum
- AMD is a degenerative, complement-driven disease rather than an autoimmune one. Common and rare variants in complement genes – most prominently the CFH Y402H risk variant, together with C3, CFB, CFI, and C2 – establish dysregulation of the alternative complement pathway as a central mechanism.
- Drusen, the extracellular deposits between the retinal pigment epithelium and Bruch’s membrane that define early and intermediate AMD, are enriched in complement proteins and oxidised lipids.
- Chronic oxidative stress on the highly metabolically active retinal pigment epithelium, compounded by smoking as the strongest modifiable risk factor, drives progressive cellular dysfunction.
- Late AMD diverges into two mechanistically distinct forms: dry AMD culminating in geographic atrophy, and neovascular (wet) AMD driven by VEGF-dependent choroidal neovascularisation. Complement inhibitors and anti-VEGF agents target these arms respectively.
- Serum supports quantification of complement components and activation products (C3, C3a, Ba, Bb, factor H, factor D), VEGF-family proteins, and oxidative and lipid biomarkers with well-established immunoassay methods.
- Because serum is acellular, it is used for immunoassay, proteomic, metabolomic, and lipidomic work; cellular AMD specimens are available separately for genotyping and cell-based studies.
Donor Stratification Available
- AMD subtype: dry (non-neovascular) versus neovascular/wet
- Disease stage: early, intermediate, or late, including documented geographic atrophy
- Laterality: unilateral versus bilateral involvement
- Treatment history: anti-VEGF-naive versus intravitreal anti-VEGF treated, and complement inhibitor exposure where applicable
- Smoking status and AREDS-type supplement use
- Age band and CFH genotype where genotyping is available
- Matched healthy controls available
Product Features
- Collected from clinically confirmed age-related macular degeneration (AMD) donors
- Processed and frozen within 24 hours of collection
- Research Use Only (RUO)
- IRB-approved protocols with documented consent
- Standard and custom aliquot volumes available
De-identified Donor Data
- AMD diagnosis confirmation
- Age, sex assigned at birth, and ethnicity
- Donor-reported allergy and infectious disease history
- AMD subtype, stage, and ophthalmic treatment history where documented
- Additional AMD-specific metadata available on request
Applications
- Complement pathway biomarker discovery, including component and activation-fragment quantification
- Serum cytokine, chemokine, and inflammatory protein profiling
- VEGF-family and angiogenic factor measurement in neovascular versus dry AMD cohorts
- Oxidative stress and lipid peroxidation marker analysis
- Untargeted serum proteomics and lipidomics for progression signatures
- Pharmacodynamic and target-engagement assay development for complement-directed therapeutics
- Diagnostic and prognostic assay development, reference-range establishment, and platform bridging
- Stratified cohort assembly for geographic atrophy progression studies
Other Age-related Macular Degeneration Specimen Types
- Age-related Macular Degeneration Plasma
- Age-related Macular Degeneration Whole Blood
- Age-related Macular Degeneration PBMC
- Age-related Macular Degeneration Leukopak
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Age-related macular degeneration serum is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare donor availability across conditions, visit our human serum page.
Applications
- Immunology and translational research
- Biomarker discovery and validation
- Drug screening and assay development
- Vaccine and infectious disease research
Product Features
- Research Use Only (RUO), Serum
- Sourced from screened, consented donors
- Processed under validated SOPs
- QC tested for purity, viability, and sterility
- Processed within 24 hours of collection
- IRB-approved protocols with electronic informed consent
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human Serum are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Serum
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Pair with a Healthy Control
Match your Age-related Macular Degeneration Serum with normal donor samples for comparison
Healthy Serum
View InventoryNeed a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.